Prothena Corporation plc (NASDAQ:PRTA) is among the best NASDAQ stocks under $50 to buy. Roche, a partner of Prothena ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...

Roche has announced that it will be advancing its Prothena-partnered investigational Parkinson’s disease (PD) drug ...

Roche RHHBY announced that it will advance pipeline candidate prasinezumab into phase III development for early-stage ...

Citizens JMP lowered the firm’s price target on Prothena Corporation plc (NASDAQ:PRTA) to $29 from $78 but kept an Outperform ...

Prothena has buried birtamimab for the second time. A phase 3 trial of the anti-amyloid antibody in the rare disease AL amyloidosis missed its primary endpoint, prompting the biotech to end ...

Today, we discuss one of these in greater detail. Prothena's program, Prasinezumab, in early Parkinson's disease is the first potentially disease-modifying antibody to demonstrate signals of ...

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease ...

For Prothena (NASDAQ: PRTA), a huge wave of attention has also come from investors since the start of the year. But has its stock price gone too high too fast? Or is this just a sign of more gains ...

A month has gone by since the last earnings report for Prothena (PRTA). Shares have added about 12.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading ...